Liraglutide (Biosimilar)

Liraglutide: a long-acting synthetic analogue of human glucagon-like peptide-1 (GLP-1), produced by recombinant DNA technology:

  • 97% similarity with human glucagon-like peptide-1
  • By binding to GLP-1 receptors, Liraglutide stimulates insulin secretion
  • Liraglutide inhibits glucagon production, inhibits gastric motility and stimulates the hypothalamic satiety center.
  • Solution for injection in multi-dose disposable pre-filled pen (subcutaneous administration)

Chemical Structure



  • as monotherapy or in combinations with other medicinal products for the treatment of type 2 diabetes.
  • weight management

AVVA’s technology features:

  • Specific E.coli strain based Technology:
    • Reduced contamination risk
    • No need for separate production line
  • established similarity to originator
  • scalable membrane filtration technology
  • robust technology
  • patent pending technology and strain

Advantages VS Originator

  • Increased biomass and target protein yield
  • less demanding on the nutrient composition
  • reduced production cycle
    • E coli vs Saccharomyces cerevisiae based technologies
    • start of sowing to the end of the induction: 6-12 hours vs 3-5 days respectively
  • optimized purification process
  • less impurities
    • 3 impurities identified in AVVA’s API
    • 4 impurities identified in originators’ API



Vasily N. Stepanenko, PhD

Head of Pilot Biotech Production at the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry


Igor V. Myagkih, PhD,

Deputy Director of the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry